| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
---|---|---|---|---|---|
Age (years) | 66 | 60 | 31 | 63 | 63 |
Sex | Female | Male | Female | Male | Male |
BMI (kg/m2) | 20.9 | 24.2 | 29.3 | 19.4 | 25.4 |
History of oncologic treatment of the liver | Hemihepatectomy | Radio-embolisation | Partial hepatectomy | None | None |
TAS-102 dosage | 50Â mg b.i.d. | 65Â mg b.i.d. | 55Â mg b.i.d. | 60Â mg b.i.d. | 70Â mg b.i.d. |
Cycle number | Cycle 2Â day 8 | Cycle 1Â day 9 | Cycle 1Â day 9 | Cycle 1Â day 9 | Cycle 1Â day 9 |
Time of response evaluation according to RECIST | After 4Â cycles TAS-102 | After 3Â cycles TAS-102 | After 3Â cycles TAS-102 | After 3Â cycles TAS-102 | After 3Â cycles TAS-102 |
Time to first disease progression (progression-free survival) | 3.7Â months | 2.8Â months | 2.8Â months | 2.8Â months | 2.8Â months |
Time between oral intake of TAS-102 and first MRS examination | 30Â min | 90Â min | 105Â min | 150Â min | 60Â min |
Timing of both localised CSI scans | 14.24Â min | 14.24Â min | 14.24Â min | 14.24Â min | 14.24Â min |